Study to assess the safety, tolerability and pharmacokinetics of AZD5055 in Japanese and Chinese healthy volunteers..

Study identifier:D8960C00005

ClinicalTrials.gov identifier:NCT05955183

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Phase-1, randomized, single-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of AZD5055 following single and multiple oral doses in Japanese and Chinese healthy volunteers.

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5055, Placebo

Sex

All

Actual Enrollment

38

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 27 Jul 2023
Primary Completion Date: 04 Dec 2023
Study Completion Date: 04 Dec 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria